Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy
NCT ID: NCT02011659
Last Updated: 2013-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
128 participants
INTERVENTIONAL
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Randomized controlled arm : Placebo versus Ramosetron injection
* Administration schedule : immediate postoperative status, 12 hrs after surgery, 36hrs after surgery
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery
NCT02478645
Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting
NCT01806948
The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery
NCT02617121
Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery
NCT03017222
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
NCT01476280
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramosetron
Ramosetron
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramosetron
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA-Class I-II
* No-definite malignancy by US, CT/MRI, CA 125 \< 500IU/ml
* Non-smoker
Exclusion Criteria
* Hx of malignancy
* Smoker
* Suspicious malignancy
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health Insurance Service Ilsan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
San-Hui Lee
Clinical assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Health Insurance Service Ilsan Hospital
Goyang-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Li SC, Wang Y, Choi SJ, Jung YS, Han KH, Chung IB, Lee SH. Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study. Obstet Gynecol Sci. 2019 Sep;62(5):344-351. doi: 10.5468/ogs.2019.62.5.344. Epub 2019 Jul 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PONV-NHIS-GYN-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.